On Invalid Date, Alimera Sciences (NASDAQ: ALIM) reported Q1 2023 earnings per share (EPS) of -$0.71, up 16.47% year over year. Total Alimera Sciences earnings for the quarter were -$4.98 million. In the same quarter last year, Alimera Sciences's earnings per share (EPS) was -$0.85.
On Invalid Date, Alimera Sciences (NASDAQ: ALIM) reported Q1 2023 revenue of $13.55 million up 13.85% year over year. In the same quarter last year, Alimera Sciences's revenue was $11.90 million.
What was ALIM's revenue growth in the past year?
As of Q2 2023, Alimera Sciences's revenue has grown -6.59% year over year. This is 13.06 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 6.47%. Alimera Sciences's revenue in the past year totalled $55.78 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.